exp date isn't null, but text field is
Neutralising monoclonal antibodies (nMABs) are recommended as a treatment option through routine commissioning for non-hospitalised ‘at risk’ adults and children (aged 12 years and above) with COVID-19.
The first nMAB available for non-hospitalised patients is Sotrovimab (Xevudy) which both blocks viral entry into healthy cells and clears cells infected with SARS-CoV-2. It became available in limited quantities from Dec 2021 for those considered to have the highest risk of progression to severe disease
Last reviewed: 29 March 2022
Next review: 29 March 2024
Author(s): Dr Conor Doherty
Version: 03/03/2022
Approved By: Scottish Paediatric and Adolescent Infection and Immunology Network